India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#405- Valuation
- ₹12,660 Cr
2023 #470 2021 #397
Market Cap
₹15,580 Cr
ALIVUS · NSE
Share Price
₹1,250.60
-1.45% today
Revenue
₹2,552 Cr
FY 2025-26 · +6.9% YoY
EBITDA
₹772 Cr
Margin 30.2%
Net Profit
₹550 Cr
FY 2025-26 · +14.9% YoY
P/E (TTM)
15.2x
P/B 2.9x
ROE
18.4%
ROCE 23.9%
Debt / Equity
0.02
Interest cover 0.8x
About Alivus Life Sciences Limited
Data last updated:
Alivus Life Sciences Limited is a public limited company based in Solapur, Maharashtra, India, a subsidiary of Nirma Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 23 June 2011 and has been in existence for over 15 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN L74900PN2011PLC139963. Its GSTIN is 27AAACZ5212E1ZL (Maharashtra). The company holds 3 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 543322 and NSE: ALIVUS.
The company has an authorised share capital of ₹46 Cr and a paid-up capital of ₹24.55 Cr. It was formerly known as Zorg Laboratories Private Limited and Glenmark Life Sciences Private Limited. It is led by directors including Yasir Yusufali Rawjee (Managing Director) and Vinod Naik (Whole-Time Director).
Its last annual general meeting (AGM) was held on 08 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Solapur, Maharashtra.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹2,551.83 Cr, a growth of 6.9% compared to the previous year. For the same year it recorded a net profit of ₹549.67 Cr (net margin 21.5%) and EBITDA of ₹771.62 Cr (EBITDA margin 30.2%). The net worth stands at ₹3,332.14 Cr (up 18.3% YoY). Total assets are valued at ₹3,425.05 Cr (up 18.4% YoY).
The company has about 2,021 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Glenmark Life Sciences and Alivus. Court records list 6 cases involving the company, including 4 filed by the company and 2 filed against it; 5 cases are pending. The company has 10 deals on record (4 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹45 Lakh; the latest was in December 2025. Its 10 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Cadila Pharmaceuticals Limited with revenue of ₹3,869.17 Cr. The company has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 293 overdue payments to 41 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glenmarklifesciences.com.
Company details
CIN L74900PN2011PLC139963
Registration Number 139963
Incorporation Date 23 June 2011
ROC Pune
Listing Status Listed - Listed on NSE (ALIVUS); Listed on BSE (543322)
Company Status Active
Date of Last AGM 08 September 2026
Date of Balance Sheet 31 March 2026
Parent Company Nirma Limited
Compliance Status Active Compliant
Name history
Alivus Life Sciences has undergone 2 name changes throughout its history. The company was previously known as Zorg Laboratories Private Limited, and Glenmark Life Sciences Private Limited. The current legal name is Alivus Life Sciences Limited.
| Company Name | Status |
|---|---|
| Alivus Life Sciences Limited | Current |
| Zorg Laboratories Private Limited | Previous |
| Glenmark Life Sciences Private Limited | Previous |
CIN history
Alivus Life Sciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74900PN2011PLC139963, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L74900PN2011PLC139963 | Current |
| U74900PN2011PTC139963 | Previous |
| U74900PN2011PLC139963 | Previous |
Key People
Yasir Yusufali Rawjee Managing Director Vinod Naik Whole-Time Director Taruvai Laxminarayanan Easwar Director Recognitions & Rankings of Alivus Life Sciences
Contact details
Alivus Life Sciences Limited's registered office is in Solapur, Maharashtra. Its website is glenmarklifesciences.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No 170 – 172 Chandramouli Industrial Estate Mohol Ba, Zarpeth, Solapur, Maharashtra, India – 413213
- IndustryPharma, API Manufacturers
To see the full contact details of Alivus Life Sciences Limited, buy the company report.
Comprehensive company report
Alivus Life Sciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Alivus Life Sciences operates two associated brands: Glenmark Life Sciences and Alivus. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| API manufacturing is provided by the CDMO in India. | glenmarklifesciences.com | |
| High-value APIs are developed and manufactured for global partners. | alivus.com |
Business activity
The main business activity of Alivus Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Alivus Life Sciences Limited, buy the company report.
Financials of Alivus Life Sciences Limited
FY 2025-26 filings availableAlivus Life Sciences Limited reported revenue of ₹2,551.83 Cr (up 6.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹2,552 Cr
+6.9% YoY
EBITDA
₹772 Cr
+13.0% YoY
Profit After Tax
₹550 Cr
+14.9% YoY
Net Worth
₹3,332 Cr
+18.3% YoY
Total Assets
₹3,425 Cr
+18.4% YoY
Total Debt
₹56.77 Cr
+0.3% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2,552 | 2,387 | 2,283 | 2,161 | 2,123 | 1,885 | 1,537 |
| Revenue growth | +6.9% | +4.5% | +5.6% | +1.8% | +12.6% | +22.6% | - |
| EBITDA | 772 | 683 | 674 | 642 | 616 | 591 | 472 |
| EBITDA margin | +30.2% | +28.6% | +29.5% | +29.7% | +29.0% | +31.4% | +30.7% |
| Profit before tax | 751 | 654 | 631 | 629 | 565 | 471 | 421 |
| Net profit | 550 | 478 | 471 | 467 | 419 | 352 | 314 |
| Net profit margin | +21.5% | +20.0% | +20.7% | +21.6% | +19.8% | +18.7% | +20.4% |
| EPS (₹) | 45.99 | 39.63 | 38.43 | 38.11 | 34.17 | 358.76 | 1,597.44 |
| Balance sheet | |||||||
| Total assets | 3,425 | 2,893 | 2,365 | 2,165 | 2,057 | 753 | 402 |
| Net worth | 3,332 | 2,817 | 2,332 | 2,138 | 2,054 | 753 | 402 |
| Total debt | 56.77 | 56.61 | 17.15 | 19.36 | 2.88 | 0.00 | 0.02 |
| Cash & bank | 2.13 | 71.24 | 302 | 309 | 512 | 116 | 10.00 |
| Net working capital | 1,369 | 1,393 | 1,480 | 1,356 | 1,382 | 178 | (147) |
| Cash flow | |||||||
| Cash from operations | 565 | 392 | 414 | 306 | 598 | 388 | 195 |
| Cash from investing | (570) | (616) | (116) | (147) | (122) | (68.73) | (50.52) |
| Cash from financing | (64.34) | (6.23) | (279) | (388) | (78.80) | (214) | (137) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 640 | 689 | 673 | 588 | 602 | 650 | 642 | 507 |
| Revenue growth (YoY) | +6.4% | +6.1% | +4.8% | +16.0% | +2.3% | - | - | - |
| Other income | 22.40 | 22.78 | 13.93 | 14.72 | 8.99 | 10.09 | 10.46 | 8.53 |
| Total expenses | 429 | 475 | 467 | 409 | 430 | 451 | 452 | 373 |
| EBITDA | 212 | 215 | 206 | 179 | 172 | 198 | 190 | 134 |
| EBITDA margin | +33.1% | +31.1% | +30.6% | +30.5% | +28.6% | +30.6% | +29.6% | +26.5% |
| Depreciation | 20.59 | 20.20 | 19.66 | 18.44 | 17.06 | 15.97 | 15.16 | 15.09 |
| Interest | 1.31 | 1.31 | 1.49 | 1.32 | 1.25 | 1.26 | 0.46 | 0.34 |
| Profit before tax | 212 | 216 | 198 | 174 | 163 | 191 | 185 | 127 |
| Tax | 52.14 | 53.14 | 48.13 | 44.11 | 41.45 | 49.43 | 48.19 | 32.14 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 24 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 640 | 689 | 673 | 588 | 602 | 650 | 642 | 507 |
| Revenue growth (YoY) | +6.4% | +6.1% | +4.8% | +16.0% | +2.3% | - | - | - |
| Other income | 22.40 | 22.78 | 13.93 | 14.72 | 8.99 | 10.09 | 10.46 | 8.53 |
| Total expenses | 429 | 475 | 467 | 409 | 430 | 451 | 452 | 373 |
| EBITDA | 212 | 215 | 206 | 179 | 172 | 198 | 190 | 134 |
| EBITDA margin | +33.1% | +31.1% | +30.6% | +30.5% | +28.6% | +30.6% | +29.6% | +26.5% |
| Depreciation | 20.59 | 20.20 | 19.66 | 18.44 | 17.06 | 15.97 | 15.16 | 15.09 |
| Interest | 1.31 | 1.31 | 1.49 | 1.32 | 1.25 | 1.26 | 0.46 | 0.34 |
| Profit before tax | 212 | 216 | 198 | 174 | 163 | 191 | 185 | 127 |
| Tax | 52.14 | 53.14 | 48.13 | 44.11 | 41.45 | 49.43 | 48.19 | 32.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,552 | 2,387 | 2,283 | 2,161 | 2,123 | 1,885 | 1,537 |
| Revenue growth | +6.9% | +4.5% | +5.6% | +1.8% | +12.6% | +22.6% | - |
| Other income | 60.41 | 34.57 | 12.04 | 28.96 | 14.70 | 0.81 | 11.99 |
| Total expenses | 1,780 | 1,704 | 1,609 | 1,519 | 1,507 | 1,294 | 1,065 |
| Employee cost | 272 | 252 | 258 | 180 | 169 | 149 | 142 |
| EBITDA | 772 | 683 | 674 | 642 | 616 | 591 | 472 |
| EBITDA margin | +30.2% | +28.6% | +29.5% | +29.7% | +29.0% | +31.4% | +30.7% |
| Depreciation | 75.36 | 60.61 | 53.45 | 42.09 | 37.88 | 33.39 | 29.37 |
| Interest | 5.37 | 2.41 | 1.55 | 0.55 | 27.96 | 87.55 | 33.52 |
| Profit before tax | 751 | 654 | 631 | 629 | 565 | 471 | 421 |
| Tax | 187 | 168 | 160 | 162 | 146 | 119 | 108 |
| Net profit | 550 | 478 | 471 | 467 | 419 | 352 | 314 |
| Net profit margin | +21.5% | +20.0% | +20.7% | +21.6% | +19.8% | +18.7% | +20.4% |
| EPS (₹) | 45.99 | 39.63 | 38.43 | 38.11 | 34.17 | 358.76 | 1,597.44 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.55 | 24.51 | 24.51 | 24.51 | 24.51 | 1.96 | 1.96 |
| Reserves & surplus | 3,308 | 2,793 | 2,308 | 2,114 | 2,030 | 751 | 400 |
| Shareholders' funds (net worth) | 3,332 | 2,817 | 2,332 | 2,138 | 2,054 | 753 | 402 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 56.77 | 56.61 | 17.15 | 19.36 | 2.88 | 0.00 | 0.02 |
| Total debt | 56.77 | 56.61 | 17.15 | 19.36 | 2.88 | 0.00 | 0.02 |
| Total liabilities | 3,425 | 2,893 | 2,365 | 2,165 | 2,057 | 753 | 402 |
| Assets | |||||||
| Gross block | 1,367 | 1,219 | 1,012 | 936 | 711 | 652 | 595 |
| Net block | 1,038 | 955 | 805 | 781 | 595 | 573 | 546 |
| Capital work in progress | 284 | 102 | 106 | 61.62 | 91.69 | 14.10 | 10.73 |
| Investments | 780 | 478 | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
| Inventories | 692 | 674 | 667 | 604 | 516 | 513 | 413 |
| Sundry debtors | 1,073 | 970 | 765 | 807 | 673 | 620 | 639 |
| Cash & bank balances | 2.13 | 71.24 | 302 | 309 | 512 | 116 | 10.00 |
| Loans & advances | 102 | 143 | 182 | 130 | 62.69 | 151 | 98.71 |
| Total current assets | 1,869 | 1,858 | 1,916 | 1,850 | 1,765 | 1,399 | 1,160 |
| Total current liabilities | 500 | 465 | 436 | 494 | 382 | 1,221 | 1,307 |
| Net working capital | 1,369 | 1,393 | 1,480 | 1,356 | 1,382 | 178 | (147) |
| Total assets | 3,425 | 2,893 | 2,365 | 2,165 | 2,057 | 753 | 402 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 71.06 | 301 | 284 | 512 | 116 | 10.00 | 2.06 |
| Net cash from operating activities | 565 | 392 | 414 | 306 | 598 | 388 | 195 |
| Net cash from investing activities | (570) | (616) | (116) | (147) | (122) | (68.73) | (50.52) |
| Net cash from financing activities | (64.34) | (6.23) | (279) | (388) | (78.80) | (214) | (137) |
| Net change in cash | (69.08) | (230) | 17.59 | (228) | 397 | 106 | 7.94 |
| Closing cash | 2.13 | 71.24 | 302 | 309 | 512 | 116 | 10.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +6.9% | +4.5% | +5.6% | +1.8% | +12.6% | +22.6% | - |
| EBITDA growth | +13.0% | +1.2% | +5.0% | +4.3% | +4.2% | +25.2% | - |
| PBT growth | +14.9% | +3.6% | +0.4% | +11.3% | +20.0% | +11.9% | +84.4% |
| Net income growth | +14.9% | +1.5% | +0.9% | +11.5% | +19.1% | +12.1% | - |
| Revenue CAGR (3Y) | +5.7% | +4.0% | +6.6% | +12.0% | +33.8% | +1861.0% | - |
| EBITDA CAGR (3Y) | +6.3% | +3.5% | +4.5% | +10.8% | +35.5% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +22.1% | +20.4% | +20.6% | +21.6% | +19.7% | +18.7% | +20.4% |
| Return on capital employed | +24.0% | +25.0% | +27.9% | +29.8% | +42.2% | +96.8% | +185.6% |
| Return on net worth | +18.4% | +18.9% | +21.1% | +22.3% | +29.8% | +60.9% | +127.8% |
| Debt / equity | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.77 | 0.39 | 0.25 | 0.09 | 4.84 | 15.70 | 7.57 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.97 | 2.14 | 2.34 | 2.62 | 3.12 | 3.02 | 2.87 |
| Inventory turnover | 3.74 | 3.56 | 3.59 | 3.86 | 4.12 | 4.07 | 3.78 |
| Debtors turnover | 2.50 | 2.75 | 2.90 | 2.92 | 3.28 | 3.00 | 2.83 |
| EPS (₹) | 45.99 | 39.63 | 38.43 | 38.11 | 34.17 | 358.76 | 1,597.44 |
| Dividend per share (₹) | 5.00 | 5.00 | 22.50 | 42.00 | 21.00 | 0.00 | 0.00 |
| Book value per share (₹) | 271.49 | 229.92 | 190.35 | 174.51 | 167.66 | 768.11 | 2,049.45 |
To see the full year-wise statements and ratios of Alivus Life Sciences Limited, buy the company report.
Board of directors of Alivus Life Sciences Limited
Alivus Life Sciences has 7 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Yasir Yusufali Rawjee | Managing Director | 26 Sep 2019 | 7 Years 0 Months | Current |
| Taruvai Laxminarayanan Easwar | Director | 08 Mar 2021 | 5 Years 7 Months | Current |
| Manju Agarwal Also directs: Gulf Oil Lubricants India Limited, Gocl Corporation Limited, Polycab India Limited and 5 more | Director | 08 Mar 2021 | 5 Years 7 Months | Current |
| Vinod Naik | Whole-Time Director | 21 Oct 2022 | 4 Years 0 Months | Current |
| Savan Rashmikant Godiawala Also directs: Carysil Limited, Elecon Engineering Company Limited, Arvind Smartspaces Limited and 2 more | Director | 25 Apr 2024 | 2 Years 6 Months | Current |
| Kaushikbhai Nandubhai Patel Also directs: Nuvoco Vistas Corporation Limited, Nirma Limited | Director | 06 Mar 2024 | 2 Years 7 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Alivus Life Sciences Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Cadila Pharmaceuticals Limited | ₹3,869.17 Cr (FY 2025) | 4.0% | Ahmedabad, Gujarat, India | |||
| Hetero Drugs Limited | ₹3,323.92 Cr (FY 2025) | 13.0% | Hyderabad, Telangana, India | |||
| Dishman Carbogen Amcis Limited | ₹2,733.18 Cr (FY 2025) | 3.0% | Ahmedabad, Gujarat, India | |||
| Covalent Laboratories Private Limited | ₹2,693.24 Cr (FY 2025) | -8.0% | Hyderabad, Telangana, India | |||
| Alivus Life Sciences Limitedthis company | ₹2,551.83 Cr (FY 2026) | ₹549.67 Cr | 21.5% | 6.9% | 2,021 | Solapur, Maharashtra, India |
| Honour Lab Limited | ₹2,482.63 Cr (FY 2025) | 4.0% | Hyderabad, Telangana, India | |||
| Aarti Drugs Limited | ₹2,403.39 Cr (FY 2025) | -5.0% | Thane, Maharashtra, India | |||
| Centrient Pharmaceuticals India Private Limited | ₹2,240.1 Cr (FY 2025) | 8.0% | Toansa, Punjab, India | |||
| Unichem Laboratories Limited | ₹2,146.29 Cr (FY 2025) | 18.0% | Mumbai, Maharashtra, India | |||
| Iol Chemicals and Pharmaceuticals Limited | ₹2,101.62 Cr (FY 2025) | -3.0% | Barnala, Punjab, India | |||
| Tianish Laboratories Private Limited | ₹2,059.53 Cr (FY 2024) | Hyderabad, Telangana, India |
To see the full peer comparison of Alivus Life Sciences Limited, buy the company report.
Auditor
Alivus Life Sciences Limited is audited by Walker Chandiok & Co LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2024 | 001076N/N500013 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 74.90%, foreign institutional investors hold 5.50%, domestic institutional investors hold 7.20% and retail and other public shareholders hold 12.40%.
Sep 2026
QUARTER
74.90% Promoters
7.20% DII (Domestic Institutional)
5.50% FII (Foreign Institutional)
12.40% Retail & Others
Promoter holding - history
Now 74.90% · Sep 2026High 74.90% · Dec 2025Low 74.90% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 74.90% | 74.90% | 74.90% | 74.90% |
| Public | 25.10% | 25.10% | 25.10% | 25.10% |
Deals & funding
Alivus Life Sciences Limited has 10 deals on record (4 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹45 Lakh; the latest was in December 2025.
Total deals
10
Market trades
4
Secondary share transfers
2
Acquisitions
2
IPO
1
Disclosed funding
₹45 Lakh
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2024 | Secondary share transfer | Undisclosed | Buyer: Nirma Limited Seller: Glenmark Pharmaceuticals Limited |
| Mar 2024 | Acquisition | ₹4,046.35 Cr | Buyer: Nirma Limited Seller: Glenmark Pharmaceuticals Limited , Others - Alivus Life Sciences Limited |
| Aug 2021 | IPO | ₹1,513.6 Cr | Investors: Ipo Alivus Life Sciences Limited, QIB Glenmark Life Sciences Limited, Polar Capital Funds PLC Healthcare Opportunities Fund Seller: Glenmark Pharmaceuticals Limited |
| Aug 2021 | Market trade | ₹72.87 Cr | Buyer: NK Securities Research Private Limited Seller: NK Securities Research Private Limited |
| Jul 2018 | Acquisition | ₹1.5 Cr | Buyer: Glenmark Pharmaceuticals Limited |
To see the full deal history of Alivus Life Sciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Alivus Life Sciences Limited has 6 court cases on record: 4 filed by Alivus Life Sciences, 2 filed against it. 5 cases are pending and 1 is disposed.
Total cases
6
Filed by the company
4
Filed against the company
2
Pending
5
Disposed
1
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 4 | 2 | 4 |
| District courts | 1 | 0 | 0 |
| Supreme Court | 1 | 0 | 1 |
Cases on record (5 of 6)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Commercial suit | Filed against the company by Incyte Holdings Corporation & Ors. | Pending |
| Supreme Court | Appeal | Filed by the company against Commissioner of CGST and Central Excise Surat II (Formerly Known As Commissioner Ce and St Ltu Mumbai) | Pending |
| High Court of Delhi | Commercial suit | Filed against the company by Vertex Pharmaceuticals Incorporated | Pending |
| High Court, GUJARAT | Special civil application | Filed by the company against an individual | Pending |
| High Court of Gujarat | Court case (SCR.A) | Filed by the company against State of Gujarat | Pending |
To see the full case history of Alivus Life Sciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Alivus Life Sciences Limited was last rated by Indiarating on 26 Feb 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Indiarating | 26 Feb 2021 |
To see the full credit ratings and regulatory alerts of Alivus Life Sciences Limited, buy the company report.
MSME payment delays
Alivus Life Sciences Limited has 2 MSME Form 1 returns on record for the period ending Sep 2019, listing 293 overdue payments to 41 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 41)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Ankleshwar Ammonia Supply Private Limited | |||
| Alaska Zyanate | |||
| Bansidhar Pharma | |||
| Preeten Healthcare Private Limited | |||
| Micron Platers |
To see the full MSME payment records of Alivus Life Sciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Alivus Life Sciences Limited has a workforce of 2,021 employees on its EPFO records as of Feb 28, 2025, across 1 active EPFO establishment.
Employee count
2,021
Active EPFO establishments
1
Employee growth
5.98%
GST
Alivus Life Sciences has 3 GST registrations: 3 active.
Total GSTINs
3
Active
3
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACZ5212E1ZL | Maharashtra | Active | 01 Jul 2017 |
| 24AAACZ5212E1ZR | Gujarat | Active | 05 Nov 2018 |
| 24AAACZ5212E2ZQ | Gujarat | Active | 15 Nov 2018 |
To see the full GST registrations and return filing status of Alivus Life Sciences Limited, buy the company report.
Recent activity
Alivus Life Sciences Limited has 32 board changes on record since 2011: 20 appointments and 12 cessations. The latest: Vijaykumar Ratilal Shah ceased to be Director on 26 Feb 2025.
AGM
Alivus Life Sciences Limited last Annual general meeting of members was held on 08 Sep 2026 as per latest MCA records.
Filing
Alivus Life Sciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Pune.
Ceased
Vijaykumar Ratilal Shah ceased to be Director.
Appointed
Savan Rashmikant Godiawala was appointed as Director.
Ceased
Gita Nayyar ceased to be Director.
Ceased
Glenn Mario Saldanha ceased to be Director.
Ceased
Sridhar Gorthi ceased to be Director.
Ceased
V S Mani ceased to be Director.
Appointed
Hiren Karsanbhai Patel was appointed as Director.
Appointed
Kaushikbhai Nandubhai Patel was appointed as Director.
Appointed
Vijaykumar Ratilal Shah was appointed as Director.
Ceased
Sumantra Mitra ceased to be Whole-Time Director.
23 earlier events are in the company report.
News
Alivus Life Sciences: Acquires 9.21% Stake In Torrent Urja 19 Private Limited For ₹14.04 Crores To Boost Renewable Energy Focus And Meet Electricity Act Standards.
Frequently asked questions
Alivus Life Sciences is an active public limited company based in Solapur, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 23 June 2011 (15+ years old) and is registered under CIN L74900PN2011PLC139963. Listed on BSE: 543322 and NSE: ALIVUS.
Alivus Life Sciences reported revenue of ₹2,551.83 Cr for FY 2025-26 (up 6.9% YoY) based on standalone financials.
Alivus Life Sciences has 7 current directors:
- Yasir Yusufali Rawjee - Managing Director
- Vinod Naik - Whole-Time Director
- Taruvai Laxminarayanan Easwar - Director
- Manju Agarwal - Director
- Savan Rashmikant Godiawala - Director
- Kaushikbhai Nandubhai Patel - Director
- Hiren Karsanbhai Patel - Director
The latest financial statements of Alivus Life Sciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 08 September 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Alivus Life Sciences is 27AAACZ5212E1ZL, registered in Maharashtra. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 24AAACZ5212E1ZR (Gujarat), 24AAACZ5212E2ZQ (Gujarat).
The CIN (Corporate Identification Number) of Alivus Life Sciences is L74900PN2011PLC139963. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Alivus Life Sciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 543322) and NSE (symbol: ALIVUS).
Alivus Life Sciences has 6 court cases on record: 4 filed by the company and 2 filed against it. 5 are pending. Most are in the high courts.
Alivus Life Sciences was incorporated on 23 June 2011, making it 15+ years old. It is registered with the Registrar of Companies, Pune.
Alivus Life Sciences has 10 deals on record (4 market trades, 2 secondary share transfers, 2 acquisitions), with disclosed funding of ₹45 Lakh; the latest was in December 2025.
The peers of Alivus Life Sciences by revenue are Cadila Pharmaceuticals Limited, Hetero Drugs Limited, Dishman Carbogen Amcis Limited, Covalent Laboratories Private Limited, Honour Lab Limited and 5 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Vijaykumar Ratilal Shah ceased to be Director on 26 Feb 2025. Savan Rashmikant Godiawala was appointed as Director on 25 Apr 2024. Gita Nayyar ceased to be Director on 22 Apr 2024. Alivus Life Sciences has 32 board changes on record in total.